Trialtrove: the go-to resource for informing clinical trial strategy, design and execution

Citeline’s Trialtrove supports trial decision-makers throughout the clinical trial life cycle, from strategy to execution. Drawing from over 60,000 sources, Trialtrove provides unmatched trial intelligence, curating data on trial benchmarks and metrics, enrollment and study timelines, patient populations, endpoints, outcomes, geographic distribution and more.

Comprehensive clinical trial data you can trust

The clinical trial landscape has never been more complex. Heightened competition for patients, changing trial design strategies and pressure to deliver on time and on budget means that now, more than ever before, you need to have access to the best possible data and insights to inform your decision-making.

But access to that all important data has also become more challenging with crucial insights tucked away in tens of thousands of different sources – websites, papers, conferences to name just a few. And that’s where Trialtrove comes in.

Professional using a laptop device to access Trialtrove for trial insights and strategy.

How it helps

Combining unmatched coverage of the clinical trial space with unparalleled detail and granularity – Trialtrove is the only resource you can rely on to help surface the insights that will inform your strategy and enable you to deliver successful trials that meet your objectives.

Benchmark objectives, endpoints and enrollment timelines. Review trial durations and uncover aspects of innovative trial design including decentralized attributes.

How it works

Surfacing data from over 60,000 sources is curated by our extensive team of therapeutically focused expert analysts and populates our industry-leading trial landscape.

Drill down to what really matters to you by employing a huge range of granular filters and indexed search terms to build a snapshot of a trial landscape that precisely mirrors your requirements. Take in details of the landscape at a high level by utilizing a flexible results table or build personalized, customizable dashboards to review the data visually.

Then dive in to the trial records to get a detailed view of every aspect of the trial in question. With links out to Trialtrove’s sister product, Sitetrove, it’s also quick and easy to view sites and investigators associated with that specific trial.

Explore Trialtrove further

Citeline Trialtrove subscriber accessing data of completed clinical trials.
MAY 17, 2024

Annual Completed Clinical Trials Report Infographic

A summary of key insights and results from our annual review of trends in clinical trials completed in 2023, based on Trialtrove data

Annual Completed Clinical Trials Report Banner
MAY 22, 2024
White paper

Annual Completed Clinical Trials Report

Key insights and results from our annual review of trends in clinical trials completed in 2023, based on Trialtrove data

a man and woman in white coat looking at a computer screen
MAY 01, 2023
White paper

2022 Completed Trials: A Roller Coaster Ride for Industry Sponsors

In 2022, Trialtrove recorded 3,881 industry-sponsored Phase I-IV clinical trials that either reached completed status or reported primary endpoints.

What's included
Improve your protocol development by analyzing current trends in trial designs and outcomes

Benchmark any aspect of your trial – from objectives and endpoints to I/E criteria and enrollment timelines. Utilize our results table views, dashboard environments and easily exportable data sets to gain the insights you need in whichever way suits you.

Spend less time searching and more time planning

With our enhanced data filtering and query capabilities, you can avoid the frustration of sifting through numerous irrelevant trial records and instead be presented with only those that match your specific criteria.

Understand the clinical strategies your competitors are using

Trialtrove is not just limited to providing insights across protocol optimization and feasibility. It is also used by thousands of individuals working in competitive intelligence, business development, licensing and many other areas as a tool to get the latest and most accurate data on candidate drug benchmarking and your competitive trial landscape.

Get direct access to our leading expert analysts

Our Ask the Analyst (AtA) service is second-to-none. Giving every subscribing user a direct, unlimited link to our therapeutically aligned expert analysts, means that for every question you need support with or additional background information you require – you can go straight to the source and get detailed responses that will further support your decision-making and analysis.

Understand more about how our solutions can help you gain a competitive advantage
Our experts
Our data is curated by the industry’s largest team of therapeutically aligned, expert analysts, making Citeline the most trusted source of R&D intelligence on the market.

Our analysis, insight and consultancy services span drug, device, company, clinical trial and market intelligence. And because our approach is interconnected, our analysts can give a broader perspective, identifying disruptive events, and in turn, helping you spot opportunities and mitigate risk.

No other company can boast our level of expertise and we are proud to be able to pass on the benefits of the approach we take to data collection, curation and analysis to our customers.
A person looking at a computer screen.
Person standing in front of a whiteboard. Person standing in an office holding a file.
Speak to a specialist

A specialist is ready to speak to you regarding your interests and find the solutions that are right for you.

Professionals submitting a form to find out more about Citeline.
Citeline may contact you about relevant products, services and content. To opt-out of these communications or to manage what you receive, please visit our Preference Center.

Your information will be used in accordance with our Privacy notice.

Thank you for your interest in Citeline. Your message has been submitted and our team will be in touch soon.